Rewinding Time. Restoring Life.

Unlocking dormant regenerative code to rebuild what chronic disease takes away.


A breakthrough in natural pluripotency—without reprogramming, without compromise.

 
 

Transformative Cell Therapy, Engineered for Regeneration

APstem is developing a first-in-class regenerative cell therapy based on a patented, proprietary stem cell platform called Guide-Integrated Adult Stem Cells (giaSCs)—also known in clinical form as APSCs. These novel stem cells are designed to address the root cause of serious chronic diseases, starting with Type 1 Diabetes Mellitus (T1D).

Unlike conventional stem cells, giaSCs are derived through a proprietary integration process that fuses immunoregulatory “guide cells” with mesenchymal stromal cells from healthy human donors. This creates a highly regenerative, immunomodulatory cell type with superior therapeutic potential and safety.

 

Apstem’s mission is rooted in restoring the body’s original regenerative potential by reawakening a dormant pluripotent blueprint that exists within the adult human body.

Unlike iPSCs or ESCs that require artificial reprogramming or ethical compromise, APstem:

  • Discovers: A dormant, naturally circulating pluripotent cell in adult human blood.

  • Activates: This cell in vitro—without genetic reprogramming or oncogenic risk.

  • Transforms: The activated cell into multiple tissue types (e.g., skin, heart, nerve, bone).

  • Restores: The regenerative intelligence that is innate but silenced after early development.

This positions Apstem as the first and only platform that achieves pluripotency naturally, safely, and scalably — a new class of regenerative medicine not bound by tumorigenic risk, immune rejection, or ethical barriers.

 

Why APstem’s giaSCs/APSCs Are Different

  • 🧬 Dual Mechanism of Action: Stimulates regeneration of lost tissue (e.g., pancreatic β-cells) and suppresses autoimmune inflammation—two key drivers of T1D and other immune-driven conditions.

  • Excellent Safety Profile: No tumorigenicity observed in long-term animal models; no need for encapsulation or immunosuppression.

  • 💉 Allogeneic, Off-the-Shelf Format: Compatible with multiple recipients; manufactured from healthy donor cells using cost-efficient GMP processes.

  • 🔄 Broad Therapeutic Applicability: Designed to treat autoimmune and degenerative diseases such as Type 1 Diabetes, IBD, and multiple sclerosis.

APstem’s platform aims to redefine stem cell medicine—by combining regenerative healing with immune balance, safely and scalably.

 

Safe, Ethical, and Regenerative

  • No gene editing

  • No embryonic material

  • No immunosuppression needed

  • No teratoma risk

This is a natural path to regeneration, and a new era in stem cell medicine.

iStock-1057830366.jpg

Discover the
World of APSCs™

iStock-514461282.jpg

A New Era in Regenerative Healing